The Marked Chart Wire · Series of events
Series of events · Moderna
Moderna shares drop on leak, then post profit
Moderna stock fell after a data leak, followed by a statement on future use and a quarterly earnings report.
Updated
The flow in 3 points
- Stock fell 25 percent after leak
- Q3 revenue hit $1.313 billion
- 2026 outlook raised to 15-25 percent
What happened, in order
Times are Eastern-
Where it began
Data leak hits stock
Shares fell about 25 percent after Phase III melanoma vaccine results reportedly leaked online, showing a 42 percent risk reduction.
Read the story -
Chief sees wider use
The chief executive stated the melanoma vaccine is anticipated to show efficacy against additional types of malignancy.
Read the story -
Latest
Q3 profit reported
Moderna reported Q3 revenue of $1.313 billion, up 29 percent, returned to GAAP profitability, and raised its 2026 revenue outlook.
Read the story
How they connect
The series begins with a stock drop following a reported data leak. This is followed by a comment on the vaccine's potential for other cancers and then a quarterly earnings report showing profit.
What to watch
- 2026 revenue growth forecast of 15-25 percent
The stocks in this series
Prices from Live · updated 9:54 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.